ACTIFED
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ACTIFED (ACTIFED).
ACTIFED contains triprolidine, a first-generation antihistamine that competitively inhibits histamine H1 receptors, and pseudoephedrine, a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion.
| Metabolism | Triprolidine: Hepatic metabolism via CYP450 enzymes. Pseudoephedrine: Partially metabolized in liver by N-demethylation; excreted unchanged in urine (70-90%). |
| Excretion | Renal: 80% (20% unchanged, 60% as metabolites). Fecal: 20% (unchanged and metabolites). Active tubular secretion of pseudoephedrine. |
| Half-life | Triprolidine: 3.2 hours; Pseudoephedrine: 5–8 hours (pH-dependent: alkaline urine prolongs). Terminal half-life for clinical use typically 4–6 hours. |
| Protein binding | Triprolidine: 60% bound to serum albumin; Pseudoephedrine: 20–30% bound to plasma proteins (mainly albumin). |
| Volume of Distribution | Triprolidine: 2.5–4.0 L/kg; Pseudoephedrine: 2.6–3.5 L/kg. Indicates extensive tissue distribution. |
| Bioavailability | Oral: Triprolidine 90–100%; Pseudoephedrine 100% (first-pass metabolism negligible). |
| Onset of Action | Oral: 30–60 minutes for antihistamine effect; 60–90 minutes for decongestant effect. |
| Duration of Action | Antihistamine: 4–6 hours; Decongestant: 4–6 hours. Extended-release formulations may last up to 12 hours. |
| Molecular Weight | 393.52 |
1 tablet (pseudoephedrine HCl 60 mg, triprolidine HCl 2.5 mg) orally every 4-6 hours; maximum 4 tablets in 24 hours.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | CrCl 30-50 mL/min: extend dosing interval to every 8 hours. CrCl 15-29 mL/min: every 12 hours. CrCl <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: consider extending interval to every 8 hours. Child-Pugh C: avoid use. |
| Pediatric use | Children 6-12 years: 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 6 hours; max 2 tablets/24 hours. Children <6 years: not recommended. |
| Geriatric use | Start with 1/2 tablet (pseudoephedrine 30 mg, triprolidine 1.25 mg) orally every 8 hours; monitor for CNS excitation and anticholinergic effects. |
| 1st trimester | Avoid during first trimester; use only if clearly needed. No well-controlled studies; potential teratogenic risk due to anticholinergic effects. |
| 2nd trimester | Use with caution; limited data suggest low risk but benefit must outweigh potential harm. |
| 3rd trimester | Avoid near term due to risk of neonatal respiratory depression, irritability, and anticholinergic effects. |
Clinical note
Comprehensive clinical and safety monograph for ACTIFED (ACTIFED).
| Placental transfer | Both active ingredients cross the placenta; pseudoephedrine has documented transfer with fetal plasma concentrations approximately 70% of maternal levels. |
| Breastfeeding | Both pseudoephedrine and triprolidine are excreted into breast milk in small amounts. Pseudoephedrine may reduce milk production and cause irritability in infants. Use with caution and monitor infant for adverse effects. |
■ FDA Black Box Warning
None.
| Serious Effects |
Severe hypertensionCoronary artery diseaseConcurrent or within 14 days of MAOI therapyNarrow-angle glaucomaUrinary retentionSevere hepatic or renal impairmentHypersensitivity to any component
| Precautions | Cardiovascular effects: hypertension, palpitations, tachycardia, arrhythmias, CNS stimulation: nervousness, dizziness, insomnia, especially in elderly, May cause urinary retention in patients with prostatic hypertrophy, Use caution in patients with diabetes, hyperthyroidism, ischemic heart disease, increased intraocular pressure, Anticholinergic effects: dry mouth, blurred vision, constipation |
| Food/Dietary | Avoid high-tyramine foods (aged cheese, cured meats, fermented products) as pseudoephedrine may potentiate vasopressor effects. Grapefruit juice may decrease pseudoephedrine absorption; separate administration by at least 4 hours. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: Limited human data; animal studies show fetal toxicity at high doses. Avoid unless benefit outweighs risk. Second/third trimesters: Risk of premature labor, neonatal respiratory depression, and withdrawal symptoms with prolonged use. Use lowest effective dose for shortest duration. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate; assess for preterm labor symptoms, uterine hyperactivity. Fetal heart rate monitoring if used near term; observe neonate for withdrawal signs if used chronically. |
| Fertility Effects | No established effect on human fertility. Animal studies show no impairment at standard doses. Theoretical risk of vasoconstriction affecting ovarian blood flow, but clinical significance unknown. |
| Clinical Pearls | Actifed (pseudoephedrine + triprolidine) is contraindicated in patients with severe hypertension, coronary artery disease, or narrow-angle glaucoma. Pseudoephedrine can cause CNS stimulation and insomnia, so avoid evening dosing. Triprolidine is a first-generation antihistamine with significant anticholinergic effects; use caution in elderly or those with BPH, urinary retention, or asthma. |
| Patient Advice | Do not take with other cold or allergy medications containing decongestants or antihistamines. · Avoid alcohol and sedatives as they may increase drowsiness. · Do not crush or chew extended-release tablets; swallow whole. · Monitor for increased blood pressure or heart rate; discontinue if palpitations occur. · May cause dizziness; avoid driving or operating heavy machinery until you know how it affects you. |